AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00014690
- Locations
- 🇺🇸
AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 174
- Registration Number
- NCT00077025
- Locations
- 🇻🇪
Research Site, Valencia, Venezuela
Iressa Versus Docetaxel (Taxotere)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-01-23
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1440
- Registration Number
- NCT00076388
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
🇦🇷Research site, El Palomar, Argentina
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 822
- Registration Number
- NCT00076076
- Locations
- 🇺🇦
ALTANA Pharma, Cities in the Ukraine, Ukraine
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1100
- Registration Number
- NCT00076089
- Locations
- 🇿🇦
ALTANA Pharma, Cities in South Africa, South Africa
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00075959
- Locations
- 🇺🇸
Research Site, Marshfield, Wisconsin, United States
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2004-01-07
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00075192
- Locations
- 🇺🇸
Research Site, Smyrna, Tennessee, United States
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-11-19
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 819
- Registration Number
- NCT00073177
- Locations
- 🇵🇪
ALTANA Pharma, Cities in Peru, Peru
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
Phase 2
Suspended
- Conditions
- First Posted Date
- 2003-07-31
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00065572
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 694
- Registration Number
- NCT00065325
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath